慢性心力衰竭基因治疗的临床研究进展

被引：10

作者：

鲁晓春

李小鹰

机构：

[1] 解放军总医院南楼心血管内科

来源：

中华老年心脑血管病杂志 | 2017年 / 19卷 / 06期

关键词：

心力衰竭; 基因疗法; 心脏移植; 肌浆网钙转运ATP酶类; 腺苷酸环化酶;

D O I：

暂无

中图分类号：

R450 []; R541.6 [血液循环衰竭];

学科分类号：

摘要：

<正>慢性心力衰竭是大多数心血管病的最终阶段,是世界范围发病率和死亡率最主要的病因之一。据估计,目前全世界超过2300万人患有慢性心力衰竭,随着老龄化社会的到来,其发病率将会在未来10年继续增长。近几十年新的医学观念和手段已经使多种心脏疾病的预后获得改观,但慢性心力衰竭死亡率（5年死亡率近50%）依然高居不下[1]。心脏移植是目前晚期心力衰竭患者最为有效的治疗手段,但供者不足、术后免疫抑制以及花费巨大严重阻碍其发展和推广。最

引用

页码：649 / 651

页数：3

共 11 条

[1] Paracrine Engineering of Human Explant-Derived Cardiac Stem Cells to Over-Express Stromal-Cell Derived Factor 1α Enhances Myocardial Repair
Tilokee, Everad L.
Latham, Nicholas
Jackson, Robyn
Mayfield, Audrey E.
Ye, Bin
Mount, Seth
Lam, Buu-Khanh
Suuronen, Erik J.
Ruel, Marc
Stewart, Duncan J.
Davis, Darryl R.
[J]. STEM CELLS, 2016, 34 (07) : 1826 - 1835
[2] The war against heart failure: the Lancet lecture[J] . Eugene Braunwald.The Lancet . 2015 (9970)
[3] Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure[J] . Barry Greenberg,Alex Yaroshinsky,Krisztina M. Zsebo,Javed Butler,G. Michael Felker,Adriaan A. Voors,Jeffrey J. Rudy,Kim Wagner,Roger J. Hajjar.JACC: Heart Failure . 2014 (1)
[4] Long-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart Failure: Analysis of Recurrent Cardiovascular Events and Mortality[J] . Krisztina Zsebo,Alex Yaroshinsky,Jeffrey J. Rudy,Kim Wagner,Barry Greenberg,Mariell Jessup,Roger J. Hajjar.Circulation Research . 2014 (1)
[5] Cardiac SERCA2A/B: Therapeutic targets for heart failure[J] . Mohammad Abrar Shareef,Lucman A. Anwer,Coralie Poizat.European Journal of Pharmacology . 2013
[6] An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure
Penn, Marc S.
Mendelsohn, Farrell O.
Schaer, Gary L.
Sherman, Warren
Farr, MaryJane
Pastore, Joseph
Rouy, Didier
Clemens, Ruth
Aras, Rahul
Losordo, Douglas W.
[J]. CIRCULATION RESEARCH, 2013, 112 (05) : 816 - 825
[7] Calcium cycling proteins and heart failure: mechanisms and therapeutics[J] . Marks,Andrew R.Journal of Clinical Investigation . 2013 (1)
[8] Gene Therapy for Heart Failure
Tilemann, Lisa
Ishikawa, Kiyotake
Weber, Thomas
Hajjar, Roger J.
[J]. CIRCULATION RESEARCH, 2012, 110 (05) : 777 - 793
[9] Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure[J] . Mariell Jessup,Barry Greenberg,Donna Mancini,Thomas Cappola,Daniel F. Pauly,Brian Jaski,Alex Yaroshinsky,Krisztina M. Zsebo,Howard Dittrich,Roger J. Hajjar.Circulation . 2011 (3)
[10] Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial[J] . Brian E. Jaski,Mariell L. Jessup,Donna M. Mancini,Thomas P. Cappola,Daniel F. Pauly,Barry Greenberg,Kenneth Borow,Howard Dittrich,Krisztina M. Zsebo,Roger J. Hajjar.Journal of Cardiac Failure . 2009 (3)

← 1 2 →